Browse drugs

…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …

…of interest in 30 GCs—these contained 15 HER2+ GCs treated with trastuzumab and T-DXd subsequently. Analysis of patient-matched samples wit…

…nalysis of the phase 3 PHILA trial confirmed the superiority of pyrotinib in combination with trastuzumab and docetaxel over placebo in c…

…whose mean age at baseline was 65 years (range: 29-89), in whom trastuzumab was used as treatment for breast cancer (82%) and gastroesophag…

…also in HCC1954 cells, which are known to exhibit resistance to trastuzumab. In vivo, treatment with trastuzumab-conjugated PTEN LNPs in HC…

…ns (3.6%), 20 irinotecan (2.0%), 196 paclitaxel (16.6%), and 21 trastuzumab (3.1%).Conclusion and Relevance A simulation analysis of a dose…

…ents and those treated with standard neoadjuvant HER2 therapies paclitaxel, with or without carboplatin, trastuzumab and pertuzumab (Taxol…

…, Rimm DL, Chuang JH, Reisenbichler E, Zarringhalam K. HER2 and trastuzumab treatment response H&E slides with tumor ROI annotations (Versi…

…reast tumors than T-DXd.Conclusions The advanced ADC, utilizing Exatecan and a super-hydrophilic polymer carrier, achieved ultra-high dr…

…l of HER2-targeting antibodies with intact Fc regions—including trastuzumab—and isotype and payload-only controls were tested. Tumor cell k…

…ional volume-derived EF (SA EF) from CMR in patients undergoing Trastuzumab treatment for breast cancer.Methods We retrospectively analysed…

…systemic therapy with fluorouracil, leucovorin, oxaliplatin and trastuzumab. This resulted in rapid clinical improvement, normalisation of …